Rational combinations of targeted cancer therapies: background, advances and challenges
H Jin, L Wang, R Bernards - Nature Reviews Drug Discovery, 2023 - nature.com
Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
[HTML][HTML] Molecular targeted therapy for anticancer treatment
HY Min, HY Lee - Experimental & molecular medicine, 2022 - nature.com
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
[HTML][HTML] PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
M He, C Cao, Z Ni, Y Liu, P Song, S Hao, Y He… - … and Targeted Therapy, 2022 - nature.com
Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
A compendium of mutational cancer driver genes
A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to developing more efficient cancer detection methods and …
transformation. This is key to developing more efficient cancer detection methods and …
RAS-targeted therapies: is the undruggable drugged?
AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
[HTML][HTML] Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …
[HTML][HTML] Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …
structures or functions that are difficult to interfere with using conventional drug design …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
[HTML][HTML] RAB31 marks and controls an ESCRT-independent exosome pathway
D Wei, W Zhan, Y Gao, L Huang, R Gong, W Wang… - Cell research, 2021 - nature.com
Exosomes are generated within the multivesicular endosomes (MVEs) as intraluminal
vesicles (ILVs) and secreted during the fusion of MVEs with the cell membrane. The …
vesicles (ILVs) and secreted during the fusion of MVEs with the cell membrane. The …
[HTML][HTML] Non-small-cell lung cancer in 2022: a review for general practitioners in oncology
H Mithoowani, M Febbraro - Current Oncology, 2022 - mdpi.com
Lung cancer is the leading cause of cancer death in Canada and a significant cause of
morbidity for patients and their loved ones. There have been rapid advances in preventing …
morbidity for patients and their loved ones. There have been rapid advances in preventing …